Co-founder Dr. Barbara Sladek was invited to speak about the newest trends in oncology.
VIENNA, December 2021: During the 4HealthTalk TV panel discussion at Puls24 Dr. Barbara Sladek gave an overview of current activities (https://bit.ly/3IyoeuV).
Further panelists were:
– Univ.-Prof. Dipl.-Ing. Dr. Georg Langs (Professor for Machine Learning in Medical Imaging, Medical University of Vienna)
– Dr Katharina Hauer (Sanofi Genzyme Medical Head & Country Medical Lead Austria)
– Sabine Loho (moderator, PULS 4)
Moreover, the exciting panel discussed how new technologies can help to improve access to healthcare systems? What new trends in the oncology arise? What will healthcare reform look like in the future?
BiomeOne describes the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker that can be used for any tumor type. Read more on BiomeOne.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.